These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. Exons 45-55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene. Echigoya Y; Lim KRQ; Melo D; Bao B; Trieu N; Mizobe Y; Maruyama R; Mamchaoui K; Tanihata J; Aoki Y; Takeda S; Mouly V; Duddy W; Yokota T Mol Ther; 2019 Nov; 27(11):2005-2017. PubMed ID: 31416775 [TBL] [Abstract][Full Text] [Related]
32. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping. Anthony K; Arechavala-Gomeza V; Ricotti V; Torelli S; Feng L; Janghra N; Tasca G; Guglieri M; Barresi R; Armaroli A; Ferlini A; Bushby K; Straub V; Ricci E; Sewry C; Morgan J; Muntoni F JAMA Neurol; 2014 Jan; 71(1):32-40. PubMed ID: 24217213 [TBL] [Abstract][Full Text] [Related]
33. Efficient Skipping of Single Exon Duplications in DMD Patient-Derived Cell Lines Using an Antisense Oligonucleotide Approach. Wein N; Vulin A; Findlay AR; Gumienny F; Huang N; Wilton SD; Flanigan KM J Neuromuscul Dis; 2017; 4(3):199-207. PubMed ID: 28869484 [TBL] [Abstract][Full Text] [Related]
34. Exons 45-55 Skipping Using Antisense Oligonucleotides in Immortalized Human DMD Muscle Cells. He M; Yokota T Methods Mol Biol; 2023; 2640():313-325. PubMed ID: 36995604 [TBL] [Abstract][Full Text] [Related]
35. Contributions of Japanese patients to development of antisense therapy for DMD. Matsuo M; Takeshima Y; Nishio H Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594 [TBL] [Abstract][Full Text] [Related]
36. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy. Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660 [TBL] [Abstract][Full Text] [Related]
37. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Anthony K; Cirak S; Torelli S; Tasca G; Feng L; Arechavala-Gomeza V; Armaroli A; Guglieri M; Straathof CS; Verschuuren JJ; Aartsma-Rus A; Helderman-van den Enden P; Bushby K; Straub V; Sewry C; Ferlini A; Ricci E; Morgan JE; Muntoni F Brain; 2011 Dec; 134(Pt 12):3547-59. PubMed ID: 22102647 [TBL] [Abstract][Full Text] [Related]
38. Toward an oligonucleotide therapy for Duchenne muscular dystrophy: a complex development challenge. Wood MJ Sci Transl Med; 2010 Mar; 2(25):25ps15. PubMed ID: 20424011 [TBL] [Abstract][Full Text] [Related]